Objectives
Circulating nucleocapsid (NCP) antigen of SARS-CoV-2 is increased in
severely ill COVID-19 patients. However, clinical deterioration of
COVID-19 often happens about one week after benign initial presentation.
The role of NCP antigenemia as a biomarker in those cases remains
unclear. We investigated NCP clearance kinetics in hospitalized patients
as a risk assessment tool for predicting necessity of intensive care
treatment of COVID-19 patients.